Monitor for any reverse split announcement or other compliance measures before the March 2027 deadline. The ongoing activist campaign (SC 13D/A filings from L.I.A. Pure Capital and Invest-Pro) adds uncertainty around board control and strategic direction, which could influence the company's ability to execute a compliance plan.
Price Chart
Executive Summary
Evogene received a Nasdaq letter granting an additional 180-day period, through March 29, 2027, to regain compliance with the $1.00 minimum bid price requirement. The company remains non-compliant and faces potential delisting if it does not cure the deficiency by the extended deadline.
Key Facts
- Nasdaq granted Evogene an additional 180-day period, until March 29, 2027, to regain minimum bid price compliance.
- The company's closing bid price has been below $1.00 per share since at least March 30, 2026.
- If compliance is not demonstrated by March 29, 2027, Nasdaq will provide written notification that Evogene's securities will be delisted.
- Evogene intends to consider options including a potential reverse share split to cure the deficiency.
- The letter has no immediate effect on Nasdaq listing or trading, and no bearing on the Tel Aviv Stock Exchange listing.
Financial Impact
Delisting risk for a micro-cap company with no stated revenue or cash runway in this filing; potential for significant shareholder value erosion if compliance is not achieved.
Risk Factors
- Failure to regain compliance by March 29, 2027, would result in Nasdaq delisting, severely impacting liquidity and access to capital markets.
- A reverse share split, while potentially curing the bid price deficiency, could further pressure the stock if not accompanied by fundamental improvements.
- Ongoing activist pressure and potential tender offer at $0.55 per share create additional uncertainty around the stock's near-term trajectory.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-004654 |
| Exhibit: exhibit_99-1.htm | 0001178913-26-004654 |
| Document: 0001178913-26-004654-index-headers.html | 0001178913-26-004654 |
| Document: 0001178913-26-004654-index.html | 0001178913-26-004654 |
| Document: 0001178913-26-004654.txt | 0001178913-26-004654 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 3 | $0.3641 | awaiting T+60 | awaiting T+60 | $0.3600 (−1.13%) |
Oct 6, 2026 21d ago | SC 13D/A | $0.4106 | awaiting T+60 | awaiting T+60 | $0.3600 (−12.32%) |
Oct 6, 2026 21d ago | 6-K | $0.4106 | awaiting T+60 | awaiting T+60 | $0.3600 (−12.32%) |
Sep 30, 2026 27d ago | 6-K | $0.4000 | awaiting T+60 | awaiting T+60 | $0.3600 (+10.00%) |
Sep 30, 2026 28d ago | EFFECT | $0.4000 | awaiting T+60 | awaiting T+60 | $0.3600 (+10.00%) |
Sep 4, 2026 7w ago | 6-K | $0.5379 | awaiting T+60 | awaiting T+60 | $0.3600 (−33.07%) |
Aug 18, 2026 10w ago | 6-K | $0.5826 | awaiting T+60 | awaiting T+60 | $0.3600 (−38.21%) |
Aug 14, 2026 10w ago | Press Release | $0.6008 | awaiting T+60 | awaiting T+60 | $0.3600 (−40.08%) |
Jul 31, 2026 12w ago | 6-K | $0.5400 $0.3466 | ▼ −35.81% | ▼ −37.60% | $0.3600 (−33.33%) |
Jun 16, 2026 19w ago | 6-K | $0.5600 $0.4806 | ▼ −14.18% | ▼ −15.18% | $0.3600 (−35.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers